Beat me to the point RE R&D! Well done!
Downie benefits - makes you do more research. Sharpe ratio through the roof on this one!
Much of the contention here centres around a point I made (without researching) and was hounded for it - why wouldn't BIT be sharing data as they go with partners etc, rather than wait for finals? This was in the BIT annual report of all places ! Too busy arguing here to see it!
https://www.annualreports.com/Company/biotron-limited
CommercialisationThe Company’s preclinical and clinical developmentactivities are undertaken with the sole aim of achievinga commercial outcome for its promising antiviralprograms.The COVID-19 pandemic and other infectious diseaseoutbreaks in recent years highlight the importanceof novel approaches such as Biotron’s viroporincompounds which have the potential to target a broadrange of existing and emerging viruses. Therapeuticdrugs such as those in development by Biotron are vitalin the fight against pandemics.
Licensing or sale of innovative technology and productsby biotechnology companies such as Biotron to majorpharmaceutical company partners first requiresdemonstration of clinical efficacy.
The Company hasbeen sharing information on its antiviral programs withpotential partners in the pharmaceutical industry sinceearly preclinical development.Discussions with pharmaceutical companies areiterative in nature. Every successful series ofexperiments or clinical trial generates another seriesof questions that will guide the decision-makingprocess on the side of commercial partners. Good,well-founded science is core to success. Feedback frompotential partners, as well as advice from experiencedinternational clinical, regulatory and industry advisorshas informed every step of development activitiesundertaken by the Company.
OutlookDuring the next financial year, the Company will be focused on:
Sharing data and discussions on its antiviral programs including the HIV-1 and COVID-19 Phase 2 clinical trialswith potential pharmaceutical company partners with a view to commercialisation of the Company’s antiviralintellectual property.
In short, per Caspex given no CR and delay, we are looking good, whatever the ST base case might be
Wow, cant believe I listened to some of the B Team ! Cat's call looking apt imo.
I wonder if these non holders are professional downies?
DYOR
